Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
The state’s insurance regulator has demanded detailed information about patients and their medications, raising privacy ...
Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...
3don MSNOpinion
My 19-year-old daughter required a treatment prescribed by her doctor. Even with my professional expertise, her doctor and I ...
His parents have now filed a lawsuit against both the pharmacy benefits-management company and Walgreens, claiming they are responsible for their son's death. The Schmidtknechts' ...
Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...
It, too, has been deemed a strong asset by investors, but it never captured significant market share against the three largest PBMs: UnitedHealth's Optum RX (UNH), CVS's Caremark, and Cigna's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results